TY - JOUR
T1 - Management of primary hepatic malignancies during the COVID-19 pandemic
T2 - recommendations for risk mitigation from a multidisciplinary perspective
AU - Barry, Aisling
AU - Apisarnthanarax, Smith
AU - O'Kane, Grainne M
AU - Sapisochin, Gonzalo
AU - Beecroft, Robert
AU - Salem, Riad
AU - Yoon, Sang Min
AU - Lim, Young-Suk
AU - Bridgewater, John
AU - Davidson, Brian
AU - Scorsetti, Marta
AU - Solbiati, Luigi
AU - Diehl, Adam
AU - Schuffenegger, Pablo Munoz
AU - Sham, Jonathan G
AU - Cavallucci, David
AU - Galvin, Zita
AU - Dawson, Laura A
AU - Hawkins, Maria A
N1 - Copyright © 2020 Elsevier Ltd. All rights reserved.
PY - 2020/8
Y1 - 2020/8
N2 - Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.
AB - Around the world, recommendations for cancer treatment are being adapted in real time in response to the pandemic of COVID-19. We, as a multidisciplinary team, reviewed the standard management options, according to the Barcelona Clinic Liver Cancer classification system, for hepatocellular carcinoma. We propose treatment recommendations related to COVID-19 for the different stages of hepatocellular carcinoma (ie, 0, A, B, and C), specifically in relation to surgery, locoregional therapies, and systemic therapy. We suggest potential strategies to modify risk during the pandemic and aid multidisciplinary treatment decision making. We also review the multidisciplinary management of intrahepatic cholangiocarcinoma as a potentially curable and incurable diagnosis in the setting of COVID-19.
KW - Betacoronavirus
KW - Bile Duct Neoplasms/therapy
KW - COVID-19
KW - Carcinoma, Hepatocellular/pathology
KW - Cholangiocarcinoma/therapy
KW - Clinical Decision-Making
KW - Coronavirus Infections/epidemiology
KW - Humans
KW - Liver Neoplasms/pathology
KW - Neoplasm Staging
KW - Pandemics
KW - Patient Care Team
KW - Pneumonia, Viral/epidemiology
KW - Risk Factors
KW - SARS-CoV-2
U2 - 10.1016/S2468-1253(20)30182-5
DO - 10.1016/S2468-1253(20)30182-5
M3 - Review article
C2 - 32511951
VL - 5
SP - 765
EP - 775
JO - The Lancet Gastroenterology and Hepatology
JF - The Lancet Gastroenterology and Hepatology
SN - 2468-1253
IS - 8
ER -